Home Cart Sign in  
Chemical Structure| 188416-29-7 Chemical Structure| 188416-29-7

Structure of (±)-Voriconazole
CAS No.: 188416-29-7

Chemical Structure| 188416-29-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

(±)-Voriconazole is a broad-spectrum antifungal agent used to treat various fungal infections such as aspergillosis and candidiasis. It exhibits antifungal activity by inhibiting ergosterol biosynthesis in the fungal cell membrane, disrupting the integrity of the fungal cell membrane.

Synonyms: (±)-UK-109496

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of (±)-Voriconazole

CAS No. :188416-29-7
Formula : C16H14F3N5O
M.W : 349.31
SMILES Code : C[C@H](C1=NC=NC=C1F)[C@](O)(C2=CC=C(F)C=C2F)CN3N=CN=C3
Synonyms :
(±)-UK-109496
MDL No. :MFCD09263753

Safety of (±)-Voriconazole

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
rat liver microsomes 0.01, 0.1, 1, 10, 25, 50, 100 µM 50 min To study the inhibitory effect of voriconazole on the metabolism of vonoprazan, IC50 was 2.93 μM, showing mixed inhibition Drug Des Devel Ther. 2020 Jun 4;14:2199-2206.
Acanthamoeba castellanii Neff (ATCC 30010, genotype T4) 13.14 ± 0.69 µM(IC50) 8, 24, 48 h To evaluate the phenomenon of programmed cell death (PCD) induced by (±)-Voriconazole, including DNA fragmentation, phosphatidylserine exposure, and caspase-like activity. Results showed that (±)-Voriconazole induced PCD in Acanthamoeba castellanii Neff. Antimicrob Agents Chemother. 2015 May;59(5):2817-24
Candida albicans 0.008 to 0.125 mg/L 24 to 72 h To evaluate the pharmacodynamic parameters of voriconazole against C. albicans, the 24-h EI50 values were 2.5 to 5 fAUC/MIC, and the 72-h EI50 values increased to 133 fAUC/MIC (EUCAST) and 94 fAUC/MIC (CLSI). Antimicrob Agents Chemother. 2020 May 21;64(6):e00170-20
human cutaneous squamous cell carcinoma B12 (SCCB12) cell lines 135 uM 14 days No significant effect of voriconazole on gene expression in SCCB12 cells was observed. Br J Dermatol. 2017 Mar;176(3):816-820
primary human keratinocytes (PHKs) 135 uM 14 days Investigated the effect of voriconazole on gene expression in PHKs, finding upregulation of cell cycle-related genes (e.g., CDC2, DLGAP5, CDKN3, and NDC80) and downregulation of keratinocyte terminal differentiation markers (e.g., SPRR3, LCE3E, and IVL). Br J Dermatol. 2017 Mar;176(3):816-820
human alveolar epithelial cells (A549 cells) 10 mg/L 48 h To evaluate the antifungal activity of voriconazole against Scedosporium apiospermum, showing that a concentration of 10 mg/liter achieved near maximal antifungal activity against all tested strains. Antimicrob Agents Chemother. 2018 Apr 26;62(5):e02516-17
Fusarium solani species complex (FSSC) biofilms >256 mg/L 24 h To evaluate the activity of voriconazole against Fusarium solani species complex biofilms, showing poor antibiofilm effects with a biofilm MIC50 >256 mg/liter. Antimicrob Agents Chemother. 2021 Oct 18;65(11):e0063821
Scedosporium apiospermum biofilms 32 mg/L 24 h To evaluate the activity of voriconazole against Scedosporium apiospermum biofilms, showing poor antibiofilm effects with a biofilm MIC50 of 32 mg/liter. Antimicrob Agents Chemother. 2021 Oct 18;65(11):e0063821

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Sprague-Dawley rats Drug interaction model Oral 30 mg/kg Single dose or 14 consecutive days To study the effect of voriconazole on the pharmacokinetics of vonoprazan, results showed that voriconazole increased the AUC, prolonged the t1/2, and decreased the CL of vonoprazan Drug Des Devel Ther. 2020 Jun 4;14:2199-2206.
Mice Neutropenic murine disseminated candidiasis model Oral 10, 20, 40 mg/kg/day Once daily for 2 days To validate the in vitro PK/PD model by simulating mouse pharmacokinetics, the 24-h EI50 values were 13.3 to 25.3 fAUC/MIC. Antimicrob Agents Chemother. 2020 May 21;64(6):e00170-20
Beagle dogs Beagle dogs Oral 7 mg/kg Single dose To study the pharmacokinetic effect of voriconazole on ripretinib in beagle dogs, the results showed that voriconazole increased the plasma exposure of ripretinib. Drug Des Devel Ther. 2021 Nov 30;15:4865-4873
BALB/c mice Immunocompromised murine model of disseminated candidiasis Intraperitoneally 12 mg/kg Twice a day for 28 days To evaluate the efficacy of voriconazole in treating Candida auris infection. Results showed that the voriconazole-treated group had significantly higher survival rates compared to the untreated group (P value = 0.009) and significant reduction in kidney tissue fungal burden (P value = 0.044). Antimicrob Agents Chemother. 2021 Aug 17;65(9):e0054921
Swiss albino mice Nonneutropenic murine model Intraperitoneal 5, 10, 20, 40 mg/kg Once daily for 7 consecutive days To evaluate the efficacy of voriconazole against wild-type and azole-resistant Aspergillus flavus isolates. Results showed that voriconazole treatment improved mouse survival in a dose-dependent manner. At 40 mg/kg, 100% efficacy was observed for 1 susceptible isolate and 1 resistant isolate (with mutation), whereas for another susceptible isolate and resistant isolate (without mutation), survival rates were 81% and 72%, respectively. Antimicrob Agents Chemother. 2016 Dec 27;61(1):e01491-16

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.86mL

0.57mL

0.29mL

14.31mL

2.86mL

1.43mL

28.63mL

5.73mL

2.86mL

 

Historical Records

Categories